Q32 Bio (NASDAQ:QTTB) Downgraded by Leerink Partnrs to Hold

Leerink Partnrs lowered shares of Q32 Bio (NASDAQ:QTTB) from a strong-buy rating to a hold rating in a research note published on Wednesday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Q32 Bio’s FY2025 earnings at ($3.38) EPS, FY2026 earnings at ($3.11) EPS, FY2027 earnings at ($3.62) EPS and FY2028 earnings at ($2.50) EPS.

Several other equities analysts have also recently weighed in on the company. BMO Capital Markets assumed coverage on Q32 Bio in a report on Friday, December 6th. They issued an “outperform” rating and a $64.00 price objective for the company. Raymond James reaffirmed an “outperform” rating and set a $22.00 price objective (down previously from $90.00) on shares of Q32 Bio in a research report on Wednesday. Oppenheimer reduced their price objective on shares of Q32 Bio from $80.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday. Piper Sandler dropped their target price on shares of Q32 Bio from $85.00 to $20.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Leerink Partners restated a “market perform” rating and set a $9.00 price objective (down from $68.00) on shares of Q32 Bio in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Q32 Bio presently has an average rating of “Moderate Buy” and a consensus target price of $29.86.

Q32 Bio Trading Down 12.9 %

Shares of Q32 Bio stock opened at $3.70 on Wednesday. Q32 Bio has a 52-week low of $3.67 and a 52-week high of $53.79. The company has a debt-to-equity ratio of 0.61, a quick ratio of 6.53 and a current ratio of 6.53. The firm has a 50-day moving average of $36.81 and a 200-day moving average of $34.13. The stock has a market cap of $45.07 million, a PE ratio of -0.26 and a beta of -0.46.

Institutional Investors Weigh In On Q32 Bio

Institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. acquired a new position in Q32 Bio during the 3rd quarter worth about $3,422,000. FMR LLC boosted its position in shares of Q32 Bio by 137.3% during the 3rd quarter. FMR LLC now owns 426,302 shares of the company’s stock valued at $19,022,000 after purchasing an additional 246,664 shares in the last quarter. Ensign Peak Advisors Inc grew its stake in Q32 Bio by 150.6% during the second quarter. Ensign Peak Advisors Inc now owns 64,481 shares of the company’s stock worth $1,157,000 after purchasing an additional 38,750 shares during the period. Harvard Management Co. Inc. bought a new stake in Q32 Bio in the second quarter worth approximately $2,925,000. Finally, Vanguard Group Inc. acquired a new position in Q32 Bio in the first quarter valued at approximately $1,836,000. 31.32% of the stock is owned by institutional investors.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.